
Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho AF, Gallagher P, Lafer B, López-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Vieta E.

[Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians.](#)

Bipolar Disorders 2018

Copyright:

This is the peer reviewed version of the above article, which has been published in final form at <https://doi.org/10.1111/bdi.12595>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

DOI link to article:

<https://doi.org/10.1111/bdi.12595>

Date deposited:

20/12/2017

Embargo release date:

20 December 2018

Title: Assessing and Addressing Cognitive Impairment in Bipolar Disorder: The International Society for Bipolar Disorders Targeting Cognition Task Force Recommendations for Clinicians

Authors: Miskowiak KW^{1,2}, Burdick KE³, Martinez-Aran A⁴, Bonnin CM⁴, Bowie CR⁵, Carvalho AF⁶, Gallagher P⁷, Lafer B⁸, López-Jaramillo C⁹, Sumiyoshi T¹⁰, McIntyre RS¹¹, Schaffer A¹², Porter RJ¹³, Purdon S¹⁴, Torres IJ¹⁵, Yatham LN¹⁵, Young AH¹⁶, Kessing LV¹, Vieta E⁴

Affiliations:¹Copenhagen Affective Disorder Research Centre (CADIC); Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Department of Psychology, University of Copenhagen, Copenhagen, Denmark, ³Department of Psychiatry, Brigham and Women's Hospital; Harvard Medical School, Boston, MA United States of America;⁴Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; ⁵Department of Psychology, Queen's University, Kingston, Canada; ⁶Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil; ⁷Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, United Kingdom; ⁸Bipolar Disorder Research Program, Departamento de Psiquiatria, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; ⁹Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia; ¹⁰Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan; ¹¹Mood Disorders Psychopharmacology Unit Brain and Cognition Discovery Foundation University of Toronto, Toronto, Canada; ¹²Department of Psychiatry, University of Toronto, Toronto, Canada; ¹³Department of Psychological Medicine, University of Otago, Christchurch, New Zealand; ¹⁴Department of Psychiatry, University of Alberta, Edmonton, Canada; ¹⁵Department of Psychiatry, University of British Columbia, Vancouver, Canada; ¹⁵Department of

Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Corresponding author: Prof. Kamilla Miskowiak, Neurocognition and Emotion in Affective Disorder (NEAD) Group, Copenhagen Affective Disorder Research Centre, Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, and Department of Psychology, University of Copenhagen, Øster Farimagsgade 2A, DK-1353 Copenhagen, Denmark. Email: Kamilla.miskowiak@regionh.dk, Tel: +45 38647087; Fax: +45 38647071.

Running head: Cognitive screening in bipolar disorder

Word count: Abstract: 250; Article body: **4,961**

Abstract

Objectives

Cognition is a new treatment target to aid functional recovery and enhance quality of life for patients with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force aimed to develop consensus-based clinical recommendations on whether, when and how to assess and address cognitive impairment.

Methods

The task force, consisting of 19 international experts from nine countries, discussed the challenges and recommendations in a face-to-face meeting, telephone conference call and email exchanges. Consensus-based recommendations were achieved through these exchanges with no need for formal consensus methods.

Results

The identified questions were: (I) Should cognitive screening assessments be routinely conducted in clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief, easy-to-administer tools such as the Screen for Cognitive Impairment in Psychiatry and Cognitive Complaints in Bipolar Disorder Rating Assessment, (III) evaluate the impact of medication and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited evidence for current evidence-based treatments but intense research efforts are underway to identify new pharmacological and/or psychological cognition treatments.

Conclusions

This task force paper provides the first consensus-based recommendations for clinicians on whether, when, and how to assess and address cognition, which may aid patients' functional recovery and quality of life.

Key words: Cognitive impairment, bipolar disorder, screening, neuropsychological, recommendations

1. Introduction

Functional recovery and quality of life are important new treatment targets for patients with bipolar disorder (BD). While sustained symptomatic remission is an achievable goal with current pharmacological and psychological treatments, patients often do not recover full functional capacity, including work and social life. Indeed, quality of life is not merely the inverse of affective symptoms but also involves patients' perceptions of their position in life in the context of their culture, values and personal aspirations (1). Poor life quality in BD is therefore closely linked to patients' lower academic attainment and vocational function (2-4), high unemployment rates (5;6), and problems with household and community functioning (7). This has led to growing consensus that clinical remission — i.e., *feeling well* — is not a sufficient treatment goal: Patients also need to *do well* and recover functionally to achieve good quality of life (8).

Persistent cognitive impairments across memory, attention, processing speed and executive function during periods of remission are directly related to poor quality of life (9) and socio-occupational outcome in BD (10-13). In fact, meta-analytic evidence indicates that memory and executive function are among the strongest contributors to occupational outcome in BD with greater impact than residual mood symptoms (13;14). According to meta-analytic evidence, cognitive impairment in the remitted phase of BD is on average of a moderate effect size (15). However, recent studies revealed substantial cognitive heterogeneity in remitted BD patients: 12-40% of patients present global cognitive impairments across several domains, 29-40% show selective deficits in attention and psychomotor speed, and 32-48% are relatively 'cognitively intact' in comparison with norms (16-18). Importantly, patients with either global or selective cognitive impairments reported poorer quality of life, more perceived stress and lower vocational function than patients who were cognitively intact despite comparable levels of residual mood symptoms (18;19). It is therefore imperative to identify patients with persistent cognitive impairment, to characterize the pattern of their impairments, and to implement

strategies for remediating these deficits to improve the clinical management of BD. To this end, there is a need for consensus on whether and how to screen for and treat cognitive impairment in clinical practice.

The International Society for Bipolar Disorders (ISBD) convened an expert task force in September 2016 under the lead of Dr. Miskowiak with the aim of developing (I) a consensus-based guidance paper for the methodology and design of cognition trials in bipolar disorder for pharmacological and non-pharmacological interventions, (II) a clinical recommendations paper for clinicians on how to address cognitive impairments in their patients, and (III) an educational patient booklet with information about cognitive impairment and pragmatic strategies for compensating for these in daily life. A paper addressing goal (I) was recently published in *Bipolar Disorders* (20). This specific paper addresses goal (II), developing consensus-based clinical recommendations by this ISBD task force that can be used by clinicians to guide their choices on whether, when and how to assess and address cognition in their patients.

2. Methods

The ISBD Targeting Cognition Task Force was initiated by Dr. Miskowiak in collaboration with Drs. Kessing and Vieta. It consists of 19 international experts in the field of cognition in mood disorders from the following nine countries (in alphabetical order): Brazil, Canada, Colombia, Denmark, Japan, New Zealand, Spain, United Kingdom, and United States of America. Members of the task force were selected based upon their expertise and include several members of a previous ISBD Cognition Task Force (21).

The process of the task force

The task force work on goal (II) was initiated with a face-to-face meeting between task force members during the ISBD Congress in Washington DC in May 2017. During the meeting, the task force reviewed, expanded and agreed upon a series of key questions and tentative recommendations to be addressed in the clinical guidance paper. This was followed up by a telephone conference in May 2017 for the task force members who had been unable to attend the ISBD congress. During the conference call, task force members discussed the identified clinical questions identified by Dr Miskowiak and associated recommendations. Consensus on the recommendations was reached through subsequent email exchanges between the task force members. The use of formal consensus methods was deemed unnecessary given high agreement amongst the task force members.

3. Results: task force recommendations

(I) Should cognitive screening assessments be implemented in the clinical management of bipolar disorder?

Objective and subjective cognitive impairment

The first questions addressed by the task force were: Should *objective* cognitive screening assessments with a short cognitive screening battery be recommended in addition to assessment of patients' self-reported cognitive difficulties? If so, should objective assessments be conducted for all patients, or only for those with either subjective cognitive complaints and/or occupational difficulties?

There was strong agreement among task force members that qualified mental health professionals trained in cognitive screening assessment should conduct formal assessment of cognition for all **adult** patients in partial or full remission (e.g., a Hamilton Depression Rating Scale [HDRS] Score <14),

whenever possible. Assessment of cognition in clinically stable, at least partially remitted patients — ideally not before 2-3 months after a mood episode — enables detection of ‘trait-related’ cognitive deficits; i.e., deficits that do not result from acute mood symptoms but persist long-term and hamper patients’ work capacity and social life (10;12;13). The recommendation to screen and track cognition in all (partially) remitted patients is based on the evidence for poor correlation between subjective and objective cognitive impairment (22-25). This implies that it is not always the patients with the most *subjective* complaints who show greatest *objective* impairments and vice versa. Indeed, patients’ insight into their own cognitive abilities relies on several factors, including metacognitive capacity and severity of mood symptoms (26). Since 30-50% remitted patients are objectively cognitively intact in comparison with norms despite subjective cognitive complaints (16;18;19), relying purely on subjectively reported difficulties could lead to a high false positive rate. At the same time, subjective assessments would also miss a considerable group of patients with unreported objective cognitive impairments due to poor insight or limited metacognitive capacity (27). Specifically, patients with BD may underreport difficulties within processing speed, attention and executive function domains (26). This is in keeping with emerging evidence that deficits in processing speed and attention domains are often mistaken for memory problems because failure to pay attention to and process information hampers subsequent recall of this information (28). Objective assessment of cognition is therefore necessary for correct identification of patients with cognitive impairment.

Notwithstanding the importance of objective cognition assessments, it is also essential to evaluate patients’ subjectively experienced cognitive problems and/or work difficulties that may originate from objective cognitive deficits. Specifically, patient-reported cognitive difficulties in daily life situations and/ or decreased work capacity are crucial for the clinical meaningfulness of implementing strategies to compensate for or treat cognitive impairment. Consequently, cognition assessments should include both objective and subjective measures. Finally, patients with cognitive performance in the normal

range, but who had high premorbid function, may be experiencing impairment relative to their true abilities even if this cannot be detected with a cognitive screening tool (where cut-offs for impairment are based on norms). Therefore, clinicians should also take into consideration patients' educational and occupational attainment as a proxy for their premorbid function. Without this consideration, clinicians may erroneously relay the idea to patients that they are not experiencing cognitive challenges and not adjusting their treatment given unobserved decline.

Brief cognitive screening

Brief cognitive screening is valuable for three key reasons: (i) to detect cognitive impairment, (ii) to identify those who are relatively cognitively intact in comparison with norms, and (iii) to track cognition over time. First, screening for objective cognitive impairment is clinically important for patients with symptoms of depression or mania close to clinical threshold, since these patients tend to display greater subjective problems than objective impairment (26). Objective neurocognitive screening assessment can clarify whether their subjective cognitive difficulties and/or socio-occupational problems are a consequence of objective cognitive impairment or secondary to other factors, such as residual mood symptoms or difficulties applying cognitive skills in complex daily life. This information can guide treatment selection to target either residual mood symptoms or cognition. Further, objective cognitive screening in patients with poor insight due to executive dysfunction (29) may clarify the extent to which objective cognitive deficits are contributing to any observed socio-occupational problems. Since the mean age of BD onset is in the late teens to early twenties (30), persistent cognitive impairments can be detrimental for academic achievement, early occupational function and interpersonal relations. Hence, detection of cognitive impairment after (partial) remission in newly diagnosed patients may help patients identify and compensate for cognitive difficulties to maintain their educational or occupational functions, thus leading to better prognosis and quality of life (see discussion of cognitive reserve under point III). In patients later in the course of illness with more

substantial functional impairments, cognitive screening assessments are also valuable as they clarify if their functional issues are at least partially rooted in cognitive deficits. This may inform compensation strategies and cognitive/ functional rehabilitation interventions (see clinical implications and treatment perspectives under points III and IV).

Second, objective cognition assessments may be useful in the management of patients presenting with concerns over ‘neuroprogression’ or dementia. A cognition assessment will enable clinicians to identify the 30-50% of patients who despite such potential concerns are objectively cognitively intact. Objective ‘proof’ that their cognitive capacity is within the normal range can provide great relief and comfort for these patients and their relatives. Nevertheless, the results of a brief cognitive screening test should always be interpreted with caution and be considered in the context of the particular clinical presentation.

Third, implementation of cognition assessments enables clinicians to track patients’ cognition over time in response to new treatments or new illness episodes. In particular, assessment of whether there is an objective change in cognition when patients have achieved (partial) remission after a medication switch may be particularly useful in cases where patients experience cognitive side-effects of their medication. If objective assessments reveal no cognitive change over time, this would provide an objective reference point for patients that reduces patients’ concerns about cognitive side-effects. In this way, cognitive screening assessments may aid treatment adherence (31) and thus indirectly improve patients’ prognosis. On the other hand, if cognition assessments do reveal cognitive decline in response to a new treatment, this could inform a change of the treatment plan to reduce the cognitive side-effects. For elderly patients, tracking cognition may be particularly useful in determining whether cognitive decline could be indicative of dementia onset. In such cases, patients should be referred to a complete diagnostic assessment. The frequency should be individualized, but ideally assessments should be made at least every 5 years or whenever there is a reason to anticipate the assessment (a

change in functioning or increased cognitive complaints, for example). However, major impediments for the detection of cognitive change are the uncertain reliability of test results and practice effects (32). Several psychometric approaches have been developed to determine ‘true’ or clinically significant change at the level of the individual patient (32). However, at this point, normative ‘cognitive change data’ are limited or unavailable for the SCIP (35) or other potential prospective cognitive screening tools in BD. This is an area of growing research and more specific guidelines are likely to become available to guide clinicians in their assessment of cognitive change within the next few years.

(II) What are the most feasible cognition screening tools in bipolar disorder?

A cognitive screening tool should be brief, easy and cost-effective for clinicians given time constraints and resource restrictions that make referral to a neuropsychologist untenable in most cases. There was consensus among task force members that the optimal way would be to have a simple, freely available “online package” which clinicians could use for all clinically stable adult patients in partial or full remission. Such a tool should include a few neurocognitive tests combined with questions about cognitive difficulties in daily life and mood status. Since there is currently no such validated online cognition screener for bipolar disorder, the Task Force agreed to explore the possibility of developing such a tool as a next goal. Until such a tool is available, the recommendations are to use available paper-and-pencil tools that are validated for detection of cognitive impairment in bipolar disorder. Two particularly feasible, easy-to-administer tools are the Screen for Cognitive Impairment in Psychiatry (SCIP; (33)) and the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA; (34)). Both tools are short and feasible and have been shown in several studies to have high internal consistency, retest reliability and concurrent validity (24;34-37).

Screen for Cognitive Impairment in Psychiatry

The SCIP is a brief cognitive screening tool consisting of five short objective tests of cognition that can be administered bedside in approximately 10-15 minutes and exists in three parallel versions to allow for repeated testing. It provides a quick quantification of significant difficulties with verbal working memory, verbal learning and memory, verbal fluency, and psychomotor speed and has high decision validity in patients with bipolar disorder (i.e., high sensitivity and specificity for cognitive impairment). The SCIP exists in several languages (in alphabetical order): Chinese (Mandarin), Danish, English, French, German, Italian, Japanese, Persian, Portuguese, Russian, and Spanish. The Danish, English, French, and German versions have been validated to detect cognitive impairment and exist with their respective norm data sets and respective cut-offs for cognitive impairment, whereas the Chinese, Italian, Japanese, Persian, Portuguese, and Russian versions exist in beta-versions (i.e., translations in need of further beta testing). These versions of SCIP (including beta-versions) can be obtained free of charge by clinicians who treat patients with bipolar disorder from the ISBD website ([URL](#)). Notably, the Spanish version of the SCIP is only commercially available via TEA Ediciones (web.teaediciones.com).

Cognitive Complaints in Bipolar Disorder Rating Assessment

The COBRA is a subjective cognitive impairment rating scale for patients with bipolar disorder that consists of 16 questions about cognitive difficulties in daily life scenarios (e.g., ‘Do you find it hard to concentrate when reading a book or a newspaper?’, ‘Do you have difficulties to find objects of daily use (keys, glasses, wristwatch...)?’, ‘Do you have the feeling that you do not finish what you begin?’). Despite general poor correlation between subjective and objective measures of cognition (22-25), the COBRA has shown some correlation with objective memory and executive function (24;34;36;37). However, when used alone, the sensitivity and specificity of the COBRA for objective cognitive impairment is suboptimal (i.e., below 70%) (24) and the instrument should therefore ideally be used in combination with an objective cognition measure such as the SCIP. The COBRA — and suggested cut-

offs for cognitive impairment — is available from the ISBD website in the following languages (in alphabetical order): Chinese, Danish, English, Japanese and Spanish. An alternative to the COBRA is the Lithium Battery-Clinical (38), a list of recommendations for clinical assessment of subjective cognitive difficulties. For example, clinicians are encouraged to ask patients about their cognitive function if patients do not present spontaneous complaints, to discuss the multifactorial influences on perceived impairment, including the influence of mood symptoms, and to track subjective cognitive function over time (38).

Cut-offs for impairment

Importantly, cut-offs for impairment on the SCIP and the COBRA should only be used as ‘rough guides’ and should always be considered in the context of patient demographics, mood state and external outcome, such as ability to work, drive, and live independently. For the SCIP, it may be advisable to use a somewhat more conservative cut-off (i.e., lower SCIP total score) for cognitive impairment in older age patients than the published norm material (24;35) given the age-related cognitive decline (39), which is potentially accelerated in mood disorders (40). Further, bipolar disorder in older age is associated with greater prevalence of dementia compared with the general population (41;42). An international expert group within the ISBD therefore recently recommended that clinicians screen cognition in older age patients using dementia sensitive instruments, such as the Mini Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) (43). Other dementia sensitive screening tests may also be used, such as the Addenbrooke's Cognitive Examination (ACE-R) and the Short Cognitive Performance Test (SKT). These instruments may be particularly suitable in cases where dementia is suspected because of ceiling effects in better functioning and/or younger patients. In addition, given the potential complexity of differentiating the cognitive deficits in late-life BD from those associated with various types of dementia, referral for full neuropsychological evaluation would be recommended in some of these cases.

While the current norm material in some studies is based on age-, gender- and IQ-matched healthy control groups, it is not age-corrected *per se*, which reflects a current limitation that may be overcome with further normative data collection. Ongoing research aims to determine the optimal SCIP and COBRA cut-offs for cognitive impairment across a range of age-groups including older age patients. Another issue with using the published SCIP norms is that cognitive impairment may be difficult to detect in patients with substantial above-normal premorbid function. Thus, is logistically feasible, clinicians may consider cognitive impairment with reference to patients' cognitive reserve as reflected by their educational level or general IQ. Since higher COBRA scores correlated with greater symptom severity (24), a more conservative cut-off (i.e. a higher COBRA score) for impairment may therefore be considered for patients with substantial subsyndromal symptoms. Finally, linking cognitive impairment to external outcomes is also important for guiding treatment steps when cognitive impairment is detected (see implications and treatment perspectives under points III and IV).

Minimum tools

In situations where it is not possible for clinicians to conduct the full SCIP and COBRA, or where these instruments are not available in the local language, the recommendation for 'minimal assessments' would be to talk with the patient about their cognitive abilities in daily life, asking them to give specific examples, and combine this interview with one or two SCIP subtests, such as the verbal fluency and coding tests (which can be easily administered in any language and require minimal time/ training). In particular, the SCIP coding test has shown sensitivity to cognitive change in response to medication effects and aging, and is therefore the recommended 'minimum tool' to track cognition over time. However, for screening purposes, cutting down the SCIP to 1-2 subtests would be at the expense of assessment validity, since the tool is already short (<15 minutes) and constitutes a minimum of what can be considered a valid cognition assessment.

Limitations of cognitive screeners

While brief cognitive screening tools can be administered by qualified mental health professionals after minimal training, take little time to administer, and are thus feasible in the clinical management of BD, these tools also have important limitations: They do not measure real life functions and cannot replace a comprehensive neuropsychological evaluation, which would give more detailed insight into which specific cognitive deficits may be related to the patients' particular psychosocial difficulties (44). The SCIP is therefore not a substitute for a comprehensive neuropsychological examination, but is merely a useful initial tool to screen patients who may benefit from a more thorough assessment to rule out cerebral pathology. For example, in cases where rapid declines in cognitive function occur (and/or accompanied by other symptoms such as confusion, headache etc.) or when function is highly discordant with current mood state/function, brief screening would *not* be adequate. Brief cognitive screening therefore cannot replace such full diagnostic evaluations, and if they show some clear deficits, this may also trigger a referral for a more comprehensive specialist assessment.

(III) What are the implications if cognitive impairment is detected on a brief tool?

It may be argued that clinicians should not screen for something if they do not have management options for the condition. While there are several promising candidate cognition treatments currently under evaluation, we currently do not have any clinically available treatment with direct pro-cognitive effects (20;45). Nevertheless, cognitive screening assessments can still improve the clinical management of BD in three important ways.

Referral to a thorough neuropsychological evaluation

First, detection of marked cognitive impairment with a cognitive screener provides a basis for referral to a thorough neuropsychological evaluation by trained neuropsychologists in certain cases. Specifically, circumstances that could warrant such a referral in the face of a ‘positive screen’ may include: (i) when there is a substantial impairment in the screening, (ii) when there is a perception of worsening in either cognition or functioning in patients assessed in the past, (iii) when there is a query about the potential organic brain illness due to a comorbid condition (e.g. substance abuse, traumatic brain illness, or dementing process), (iv) when there is a desire to evaluate multiple cognitive domains implicated in bipolar disorder (e.g. sustained attention, verbal and nonverbal declarative memory, multiple executive functions including response inhibition, fluency, working memory, attentional shifting, mental flexibility, organization, and planning) for treatment or rehabilitative purposes, (v) when there are concerns about the patient’s motivation or effort during cognitive screening and thus the validity of test results, or (vi) when there are likely premorbid/developmental/learning problems that may complicate the cognitive picture.

Evaluation of ‘secondary’ causes of cognitive deficits

Second, cognitive screening during partial or full remission can provide a basis for evaluation of the potential impact of medical or psychiatric comorbidity, and medication on cognition. Clinicians could be prompted by a positive screen to ascertain for potential ‘secondary’ causes of cognitive deficits due to psychiatric comorbidity (e.g., alcohol use disorder or ADHD), medical comorbidity (e.g., cerebrovascular disease, diabetes, elevated ammonia levels or uncontrolled hypothyroidism), substantial subthreshold depressive symptoms and medications (e.g., antipsychotics, elevated serum levels of lithium or anticonvulsants, and benzodiazepines). This can be useful for optimization of patients’ treatments to reduce cognitive impairments; for example, reducing antipsychotic medication and benzodiazepine use or ensuring that serum mood stabilizer levels are within the recommended range. It is important to consider and address these common causes of secondary or pseudo-specific

cognitive deficits before a ‘true’ illness-associated cognitive impairment can be assumed. In many cases, addressing such secondary causes of cognitive deficits will result in significant cognitive improvement.

Patient recommendations

Detection of persistent cognitive impairments can provide a basis for recommendation of compensational strategies, adjustment of work responsibilities or rehabilitative interventions to improve functioning. Specifically, the assessments can be used to inform patients and their relatives about the nature and consequences of cognitive impairment which may help patients tackle and compensate for these difficulties in daily life. By increasing patients’ and their families’ insight into the nature and impact of residual cognitive impairments, the assessments may encourage patients to implement compensation strategies and reduce potential interpersonal problems (for example, family members’ irritation or disappointment when patients forget daily chores or anniversaries). When patients wish to resume work, brief assessment of their cognitive status can become an important basis for adjustment of work demands and reduce expectations so they are realistic. Finally, cognitive screening assessment can also provide impetus for good habits including getting regular and sufficient sleep and physical exercise, restricting alcohol intake, and adhering to treatment.

Another important way of reducing cognitive impairment in bipolar disorder is implementation of strategies to boost patients’ cognitive reserve, the capacity of the brain to tolerate neuropathology, reduce symptom manifestations and manage cognitive challenges (46). Specifically, high cognitive reserve – which is estimated by patients’ premorbid IQ, educational level and occupational attainment(47) – is thought to slow down the clinical presentation of neurocognitive decline whereas low cognitive reserve may exacerbate cognitive decline (46;48). Cognitive screening assessments can

motivate patients to build up their cognitive reserve to prevent further cognitive decline and even improve their cognitive outcome.

(IV) What are the treatment perspectives?

There are no available treatments with documented direct pro-cognitive effects in bipolar disorder despite the pressing need for such treatments to enhance functional recovery and reduce societal costs (20). The unmet clinical need is partially due to several major methodological challenges in cognition trials in bipolar disorder, which have been addressed and discussed by the task force in a recently published methodological guidance paper (20). However, current research effort is likely to reveal effective pharmacological and psychological treatments within the next few years.

Promising pharmacological treatments

Among the most promising candidate pharmacological treatments are the corticosteroid receptor antagonist mifepristone, the atypical antipsychotic lurasidone, the multifunctional neurotrophic growth factor erythropoietin (EPO), the antidepressant vortioxetine and non-amphetamine stimulant modafinil. In particular, two studies of mifepristone (a one-week cross-over study and a three-week parallel study) in moderately depressed patients with bipolar disorder found beneficial effects on spatial working memory (but not on other cognitive domains) (49;50). Further, a recent randomized, open-label study recently found beneficial effects of six weeks treatment with lurasidone on a global measure of cognition in euthymic patients with bipolar disorder type I (51). A large multicenter RCT of six weeks lurasidone treatment for cognitive impairment in bipolar disorder is underway (<https://clinicaltrials.gov/ct2/show/NCT02731612>). Finally, two parallel RCTs investigating the effects of EPO trials in partially remitted patients with bipolar disorder and in treatment-resistant unipolar

depression revealed beneficial effects across several cognitive domains (52-54). Based on this, two new parallel RCTs have recently been initiated to examine the effects of 12-weeks EPO treatment of cognitively impaired patients with bipolar disorder and their first-degree relatives, respectively (Petersen et al, in prep.). In addition to the above mentioned candidate treatments with preliminary evidence for efficacy on cognition in bipolar disorder, there are several compounds that have shown promising effects in unipolar disorder. Modafinil – which was originally intended to treat narcolepsy – is a promising candidate treatment based on findings from a recent RCT in remitted patients with unipolar disorder. Specifically, beneficial effects of a single dose (200 mg) modafinil over placebo were observed on episodic memory and working memory (but not on executive function or sustained attention) in these remitted patients (55). Further, the antidepressant vortioxetine was found in several RCTs to improve some aspects of cognition in unipolar disorder, which seems to be partially independent of its antidepressant actions and was also recently shown in remitted patients (56;57). Studies are therefore warranted to investigate the ability of these compounds to improve cognitive function in bipolar disorder.

Promising psychological treatments

Promising psychological treatments for cognitive and functional impairments in bipolar disorder are functional remediation (FR) and certain cognitive remediation (CR) programs including action-based cognitive remediation (ABCR). Functional remediation and ABCR both involve cognitive training, compensation techniques and coping strategies to overcome cognitive difficulties in daily life situations. However, while FR focuses primarily on the training of neurocognitive strategies and psychosocial skills (58), ABCR emphasizes computerized cognitive training and transfer of the learned skills to daily life challenges by practical in-session exercises and actively seeking cognitive challenges in daily life. Functional remediation seems a viable option for patients presenting cognitive and psychosocial impairments because it has shown to be effective at improving functioning in patients in

late states of illness (58;59). While a large RCT did not show significant benefits of 21 weeks FR on cognition, this may be because of the study design that involved enrichment for functional impairment but not for cognitive deficits (58). Indeed, exclusion of the patients who were cognitively intact revealed a significant treatment benefit on verbal memory function (60). In addition, several naturalistic or quasi-experimental studies of different CR programs for bipolar disorder have been investigated over the past decade with encouraging preliminary results (61-65), although the only published RCT of 12-weeks group-based CR showed no efficacy on objective cognition (66). Notably, a non-randomized controlled trial of 10 weeks of ABCR was recently found to improve not only cognition but also vocational function in a mixed group of patients with severe mental illnesses (schizophrenia, unipolar and bipolar disorder) (67). Based on this evidence, two parallel RCTs were recently set up to investigate the effects of 10 weeks ABCR in cognitively impaired patient with bipolar disorder in remission and their first-degree relatives (68). Other ongoing RCTs investigate the effects of 12 weeks of cognitive-behavioral rehabilitation (69), 12 weeks of cognitive remediation (70) and 24 weeks internet-based cognitive remediation for BD I (71).

A highly promising treatment perspective is the combination of pharmacological and psychological interventions (e.g., (72)). This is likely to produce synergistic effects on brain function that may translate into more robust efficacy on cognition and functional outcome than either treatment modality alone. Multimodal treatment approaches are therefore considered a key next step for cognition trials in bipolar disorder that is likely to reveal new effective treatment options.

4. Conclusions

Cognition is a new key treatment target in bipolar disorder but there has been a lack of consensus on how cognitive impairment should be assessed and managed. This ISBD Targeting Cognition Task

Force paper provides the first consensus-based recommendations for clinicians on whether and how to assess and address cognition in their patients. The task force addressed questions about (I) whether and when to conduct cognitive screening assessments, (II) what screening tools are most feasible, (III) what the implications are if impairment is detected, and (IV) which treatment perspectives there are for improving cognition and functioning in BD. The recommendations are summarized in Table 1 and displayed in Figure 1. Key recommendations are that clinicians: (I) conduct formal assessment of cognition for all patients in partial or full remission whenever possible, (II) use brief, feasible tools that include objective and subjective cognition measures such as the SCIP and COBRA, which exist in multiple languages and are freely available through the ISBD website, (III) evaluate the potential impact of medication, comorbidity and symptoms when impairment is detected, refer for more comprehensive neuropsychological evaluation when clinically indicated, use the assessments to encourage patients to build up their cognitive reserve. Regarding (IV), there is currently no clinically available treatment with efficacy on cognition but intense research effort is likely to reveal new effective pharmacological, psychological and multimodal treatments in the near future.

Acknowledgments

The authors thank the International Society for Bipolar Disorders executives and staff for their support with organizing this task force. The Lundbeck Foundation and Weimann Foundation are acknowledged for their contributions to KWM's salary for her to do full-time clinical research.

Disclosures

KWM reports having received consultancy fees from Lundbeck and Allergan. **KEB** has served on advisory boards for Sunovion, Sumitomo Dainippon, Takeda-Lundbeck, and Neuralstem. **AMA** has received funding for research projects and/or honoraria as a consultant or speaker for the following companies and institutions: Otsuka, Pfizer, AstraZeneca, Bristol-Myers Squibb, Lundbeck, Brain and Behaviour Foundation (NARSAD Independent Investigator), the Spanish Ministry of Economy and Competitiveness and Instituto de Salud Carlos III. **CRB** has been a consultant or advisor for BoehringerIngelheim, Lundbeck, Otsuka, and Takeda and has received grant money from Pfizer and Takeda. **RSM** is a consultant and/or receives honorarium from speaking from Sunovion, Johnson & Johnson, Otsuka, Lundbeck, Pfizer, Allergan, BMS, Shire, and Purdue. **CLJ** has received grants from: COLCIENCIAS, Universidad de Antioquia-CODI, NIMH. He has served as a consultant, advisor or Continuing Medical Education (CME) speaker for the following companies: AstraZeneca, Eli Lilly, Glaxo-SmithKline, Janssen, Lundbeck and Pfizer. **AS** has been a consultant or received honoraria from Allergan, BMS, Lundbeck, Otsuka, and Sunovion. **IJT** has received consultant fees from Lundbeck and Sumitomo Dainippon. **RJP** uses Software for research at no cost from Scientific Brain Training Pro. **TS** has received honoraria for advisory board, consultations, and/or speaker's role from Dainippon Sumitomo Pharmaceutical, Meiji Seika Pharma, Novartis, Otsuka Pharmaceutical and Takeda. **LNY** has been on speaker/advisory boards for, or has received research grants from Alkermes, Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Dainippon Sumitomo Pharma, Janssen, Lundbeck, Otsuka, Sunovion, and Teva. **AHY** is employed by King's College London, is honorary Consultant for SLaM (NHS UK). He has given paid lectures and is on advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders. He has no shareholdings in pharmaceutical companies. He has investigator-initiated studies from AZ, Eli Lilly and Lundbeck. **LVK** has within the preceding three years been a consultant for Lundbeck, AstraZeneca and Sunovion. **EV** has received grants, CME-related honoraria, or consulting fees from AB-Biotics, Alexza, Almirall,

Angelini, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Ferrer, ForestResearch Institute, Gedeon Richter, GlaxoSmith-Kline, Janssen, Janssen-Cilag, Jazz, Johnson & Johnson, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Pierre-Fabre, Qualigen, Roche, Sanofi-Aventis, Schering, Plough, Servier, Shire, Solvay, Takeda, Teva, CIBERSAM, the Seventh European Framework Programme (ENBREC), the Stanley medical Research Institute, United Biosource Cooperation, and Wyeth. All other authors report no biomedical financial interests or potential conflicts of interest.

Reference List

- (1) The WHOQOL group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. *Soc Sci Med* 1995 Nov;41(10):1403-9.
- (2) Glahn DC, Bearden CE, Bowden CL, Soares JC. Reduced educational attainment in bipolar disorder. *J Affect Disord* 2006 Jun;92(2-3):309-12.
- (3) Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. *J Clin Psychiatry* 2002 Feb;63(2):120-5.
- (4) Marwaha S, Durrani A, Singh S. Employment outcomes in people with bipolar disorder: a systematic review. *Acta Psychiatr Scand* 2013 Sep;128(3):179-93.
- (5) Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. *Bipolar Disord* 2007 Feb;9(1-2):183-96.
- (6) Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang HW, et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Bipolar Disord* 2004 Dec;6(6):460-9.
- (7) Decker L, Träger C, Miskowiak K, Waehrens E, Vinberg M. Ability to perform Activities of Daily Living among patients with bipolar disorder in remission. *Edorium Journal of Disability and Rehabilitation* 2017;((accepted pending minor corrections)).
- (8) Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. *World Psychiatry* 2016 Oct;15(3):288-9.
- (9) Mackala SA, Torres IJ, Kozicky J, Michalak EE, Yatham LN. Cognitive performance and quality of life early in the course of bipolar disorder. *J Affect Disord* 2014 Oct;168:119-24.
- (10) Bonnin CM, Martinez-Aran A, Torrent C, Pacchiarotti I, Rosa AR, Franco C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. *J Affect Disord* 2010 Feb;121(1-2):156-60.
- (11) Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. *Bipolar Disord* 2007 Feb;9(1-2):103-13.
- (12) Torrent C, Martinez-Aran A, del Mar BC, Reinares M, Daban C, Sole B, et al. Long-term outcome of cognitive impairment in bipolar disorder. *J Clin Psychiatry* 2012 Jul;73(7):e899-e905.
- (13) Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. *Bipolar Disord* 2014 May;16(3):217-29.

- (14) Depp CA, Mausbach BT, Harmell AL, Savla GN, Bowie CR, Harvey PD, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. *Bipolar Disord* 2012 May;14(3):217-26.
- (15) Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand* 2013 Sep;128(3):149-62.
- (16) Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med* 2014 Oct;44(14):3083-96.
- (17) Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. *J Affect Disord* 2016 Nov 15;205:378-86.
- (18) Sole B, Jimenez E, Torrent C, del Mar BC, Torres I, Reinares M, et al. Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved. *Bipolar Disord* 2016 May;18(3):288-99.
- (19) Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder. (under review) . 2016.
Ref Type: Journal (Full)
- (20) Miskowiak K, Burdick K, Martinez-Aran A, Bonnin C, Bowie C, Carvalho A, et al. Methodological Recommendations for Cognition Trials in Bipolar Disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. *Bipolar Disord*. (in press). 2017.
Ref Type: Journal (Full)
- (21) Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). *Bipolar Disord* 2010 Jun;12(4):351-63.
- (22) Burdick KE, Endick CJ, Goldberg JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? *Psychiatry Res* 2005 Jul 15;136(1):43-50.
- (23) Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. *Psychiatry Res* 2015 Sep 30;229(1-2):565-71.
- (24) Jensen JH, Støttrup MM, Nayberg E, Knorr U, Ullum H, Purdon SE, et al. Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. *J Affect Disord* 2015;187(10):19.
- (25) Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? *Nord J Psychiatry* 2012 Sep;66(4):248-53.

- (26) Miskowiak KW, Petersen JZ, Ott CV, Knorr U, Kessing LV, Gallagher P, et al. Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. *Acta Psychiatr Scand* 2016 Dec;134(6):511-21.
- (27) Van Camp LS, Oldenburg JF, Sabbe BG. How self-reflection and self-certainty are related to neurocognitive functioning: an examination of cognitive insight in bipolar disorder. *Cogn Neuropsychiatry* 2016;21(2):130-45.
- (28) Li Y, Root JC, Atkinson TM, Ahles TA. Examining the Association between Patient-Reported Symptoms of Attention and Memory Dysfunction with Objective Cognitive Performance: A Latent Regression Rasch Model Approach. *Arch Clin Neuropsychol* 2016 Jun;31(4):365-77.
- (29) Yen CF, Cheng CP, Ko CH, Yen JY, Huang CF, Chen CS. Relationship between insight and neurocognition in patients with bipolar I disorder in remission. *Compr Psychiatry* 2008 Jul;49(4):335-9.
- (30) Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet* 2015 Sep 17.
- (31) Mago R, Borra D, Mahajan R. Role of adverse effects in medication nonadherence in bipolar disorder. *Harv Rev Psychiatry* 2014 Nov;22(6):363-6.
- (32) Duff K. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. *Arch Clin Neuropsychol* 2012 May;27(3):248-61.
- (33) Purdon S. *The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties* . 2005. Alberta, Canada, Edmonton.

Ref Type: Generic

- (34) Rosa AR, Mercade C, Sanchez-Moreno J, Sole B, Mar Bonnin CD, Torrent C, et al. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). *J Affect Disord* 2013 Aug 15;150(1):29-36.
- (35) Rojo E, Pino O, Guilera G, Gomez-Benito J, Purdon SE, Crespo-Facorro B, et al. Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). *Schizophr Res* 2010 Feb;116(2-3):243-51.
- (36) Toyoshima K, Fujii Y, Mitsui N, Kako Y, Asakura S, Martinez-Aran A, et al. Validity and reliability of the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) in Japanese patients with bipolar disorder. *Psychiatry Res* 2017 Aug;254:85-9.
- (37) Xiao L, Lin X, Wang Q, Lu D, Tang S. Adaptation and validation of the "cognitive complaints in bipolar disorder rating assessment" (COBRA) in Chinese bipolar patients. *J Affect Disord* 2015 Mar 1;173:226-31.
- (38) Malhi GS, McAulay C, Gershon S, Gessler D, Fritz K, Das P, et al. The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder. *Bipolar Disord* 2016 Mar;18(2):102-15.
- (39) Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. *Clin Geriatr Med* 2013 Nov;29(4):737-52.

- (40) Gualtieri CT, Johnson LG. Age-related cognitive decline in patients with mood disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2008 May 15;32(4):962-7.
- (41) Chen MH, Li CT, Tsai CF, Lin WC, Chang WH, Chen TJ, et al. Risk of subsequent dementia among patients with bipolar disorder or major depression: a nationwide longitudinal study in Taiwan. *J Am Med Dir Assoc* 2015 Jun 1;16(6):504-8.
- (42) da SJ, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. *Br J Psychiatry* 2013 Mar;202(3):177-86.
- (43) Rej S, Quayle W, Forester BP, Dols A, Gatchel J, Chen P, et al. Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature. *Bipolar Disord* 2017 Nov 6.
- (44) Roebuck-Spencer TM, Glen T, Puente AE, Denney RL, Ruff RM, Hostetter G, et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological Test Batteries: A National Academy of Neuropsychology Education Paperdagger. *Arch Clin Neuropsychol* 2017 Jun 1;32(4):491-8.
- (45) Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. *Eur Neuropsychopharmacol* 2016 Oct 13.
- (46) Grande I, Sanchez-Moreno J, Sole B, Jimenez E, Torrent C, Bonnin CM, et al. High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. *J Affect Disord* 2016 Oct 18.
- (47) Stern RA, Silva SG, Chaisson N, Evans DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. *Arch Neurol* 1996 Feb;53(2):148-53.
- (48) Forcada I, Mur M, Mora E, Vieta E, Bartres-Faz D, Portella MJ. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. *Eur Neuropsychopharmacol* 2015 Feb;25(2):214-22.
- (49) Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. *Biol Psychiatry* 2012 Dec 1;72(11):943-9.
- (50) Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. *Neuropsychopharmacology* 2004 Aug;29(8):1538-45.
- (51) Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. *Lancet Psychiatry* 2017 Feb 6.
- (52) Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind,

randomized, placebo-controlled phase 2 trial. *Neuropsychopharmacology* 2014 May;39(6):1399-408.

- (53) Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. *J Clin Psychiatry* 2014 Jul 8.
- (54) Ott CV, Vinberg M, Kessing LV, Miskowiak KW. The effect of erythropoietin on cognition in affective disorders - Associations with baseline deficits and change in subjective cognitive complaints. *Eur Neuropsychopharmacol* 2016 Aug;26(8):1264-73.
- (55) Kaser M, Deakin J, Michael A, Zapata C, Bansal R, Ryan D, et al. Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. *Biological Psychiatry* CNNI 2017;(in press).
- (56) McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. *Int J Neuropsychopharmacol* 2016 Aug 24.
- (57) Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. *Mol Psychiatry* 2017 May 23.
- (58) Torrent C, Bonnin CM, Martinez-Aran A, Valle J, Amann BL, Gonzalez-Pinto A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. *Am J Psychiatry* 2013 Aug;170(8):852-9.
- (59) Bonnin CM, Torrent C, Arango C, Amann BL, Sole B, Gonzalez-Pinto A, et al. Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. *Br J Psychiatry* 2016 Jan;208(1):87-93.
- (60) Bonnin CM, Reinares M, Martinez-Aran A, Balanza-Martinez V, Sole B, Torrent C, et al. Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. *Psychol Med* 2015 Sep 21;1-11.
- (61) Deckersbach T, Nierenberg AA, Kessler R, Lund HG, Ametrano RM, Sachs G, et al. RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms. *CNS Neurosci Ther* 2010 Oct;16(5):298-307.
- (62) Meusel LA, Hall GB, Fougere P, McKinnon MC, MacQueen GM. Neural correlates of cognitive remediation in patients with mood disorders. *Psychiatry Res* 2013 Nov 30;214(2):142-52.
- (63) Naismith SL, Redoblado-Hodge MA, Lewis SJ, Scott EM, Hickie IB. Cognitive training in affective disorders improves memory: a preliminary study using the NEAR approach. *J Affect Disord* 2010 Mar;121(3):258-62.

- (64) Preiss M, Shatil E, Cermakova R, Cimermanova D, Ram I. Personalized cognitive training in unipolar and bipolar disorder: a study of cognitive functioning. *Front Hum Neurosci* 2013;7:108.
- (65) Veeh J, Kopf J, Kittel-Schneider S, Deckert J, Reif A. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. *Int J Bipolar Disord* 2017 Dec;5(1):8.
- (66) Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. *PLOS ONE* 2015;10(6):e0127955.
- (67) Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based cognitive remediation for individuals with serious mental illnesses: Effects of real-world simulations and goal setting on functional and vocational outcomes. *Psychiatr Rehabil J* 2017 Mar;40(1):53-60.
- (68) Ott C, Vinberg M, Bowie C, Christensen E, Kessing LV, Miskowiak K. Effect of Action-Based Cognitive Remediation on cognition and neural activity in bipolar disorder and healthy first-degree relatives: study protocol for a randomised controlled trial. *Trials* 2017;Under review.
- (69) Gomes BC, Rocca CC, Belizario GO, Lafer B. Cognitive-behavioral rehabilitation vs. treatment as usual for bipolar patients: study protocol for a randomized controlled trial. *Trials* 2017 Mar 28;18(1):142.
- (70) Strawbridge R, Fish J, Halari R, Hodsoll J, Reeder C, Macritchie K, et al. The Cognitive Remediation in Bipolar (CRiB) pilot study: study protocol for a randomised controlled trial. *Trials* 2016 Jul 29;17:371.
- (71) Lewandowski KE, Sperry SH, Ongur D, Cohen BM, Norris LA, Keshavan MS. Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial. *Trials* 2016 Mar 12;17(1):136.
- (72) Breitborde NJ, Dawson SC, Woolverton C, Dawley D, Bell EK, Norman K, et al. A randomized controlled trial of cognitive remediation and d-cycloserine for individuals with bipolar disorder. *BMC Psychol* 2014;2(1):41.

Table 1: Quick guide with a summary of the ISBD task force recommendations.

Clinical Recommendations for Assessment of Cognition in Bipolar Disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force	
Quick guide	
(I) Should cognitive screening assessments be conducted?	
<ul style="list-style-type: none"> • Conduct formal screening assessment of cognition for <i>all patients in partial or full remission</i> whenever possible since subjective and objective cognition measures correlate poorly 	
<ul style="list-style-type: none"> • Assess objective and subjective cognition to: (i) detect cognitive impairment that should be addressed and in some cases may require referral for comprehensive neuropsychological evaluation, (ii) identify those who are cognitively intact, and (iii) track cognition, ideally at least every 5 years or whenever there is a reason to anticipate the assessment 	
(II) What are the most feasible tools?	
<ul style="list-style-type: none"> • Use brief, feasible tools that include objective and subjective cognition measures such as the Screen for Cognitive Impairment in Psychiatry (SCIP) and Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) 	
<ul style="list-style-type: none"> • Obtain the SCIP and COBRA- which exist in multiple languages and are freely available - through the ISBD website at (URL) 	
(III) What are the implications if cognitive impairment is detected?	
<ul style="list-style-type: none"> • Evaluate the potential impact of medication, comorbidity and symptoms when impairment is detected to discriminate between ‘secondary’ and ‘primary’ causes of cognitive impairments – and adjust medication if necessary to reduce cognitive side-effects 	
<ul style="list-style-type: none"> • Consider referral for more comprehensive neuropsychological evaluation when there is a substantial impairment in the screening, when there is concern of organic brain illness, comorbidity, or cognitive decline, when there is a need to evaluate multiple cognitive domains in greater detail, when there is a question of poor effort affecting validity of test results, or when premorbid/developmental/learning problems may be complicating the cognitive picture. 	
<ul style="list-style-type: none"> • Inform patients and relatives about the nature and possible consequences of patients’ cognitive impairments and encourage compensation strategies, support and adjustment of expectations 	
<ul style="list-style-type: none"> • Encourage patients to implement good habits, including regular sleep and exercise and to build up their cognitive reserve by engaging in education and vocational activities 	
(IV) What are the treatment perspectives?	
<ul style="list-style-type: none"> • There is currently no clinically available treatment with efficacy on cognition but intense research effort is likely to reveal effective treatments within the next few years 	
<ul style="list-style-type: none"> • Promising pharmacological candidate treatments are: mifepristone, lurasidone, erythropoietin (EPO), vortioxetine and modafinil 	
<ul style="list-style-type: none"> • Promising psychological interventions are functional remediation and cognitive remediation programs including action-based cognitive remediation 	